1st Mar 2006 09:00
AstraZeneca PLC01 March 2006 Dealing by Directors Companies Act 1985 Sections 324/329 Transaction by Persons Discharging Managerial Responsibilities Disclosure Rules DR 3.1.2R We hereby inform you that the interest of David R. Brennan, a Director of theCompany, in the shares of AstraZeneca PLC has changed as detailed below. MrBrennan has interests in both the Ordinary Shares and the American DepositaryShares (ADSs) of AstraZeneca PLC. One ADS equals one Ordinary Share. On 24 February 2006, Mr Brennan received an allocation of 6,352 Ordinary Sharesunder the previously disclosed arrangements relating to his annual bonus for2005 whereby he is required to defer a portion of the bonus earned into sharesfor a period of three years. The shares were allocated at a price of 2639 penceper share. Mr Brennan will become beneficially entitled to these shares on 24February 2009. On 24 February 2006, Mr Brennan received a scheduled distribution out of theAstraZeneca US Executive Deferral Plan, a unitised stock fund established in2000, in which Mr Brennan, in common with other participating US executives, isdeemed to have a notional interest in ADSs calculated by reference to the fundvalue and the closing price of AstraZeneca ADSs. Following this scheduleddistribution on 24 February 2006, Mr Brennan had a notional interest in 70,387ADSs within the AstraZeneca US Executive Deferral Plan by reference to theclosing price on 24 February 2006 of US$46.14. On 27 February 2006, Mr Brennan purchased, on his own account, additional ADSsto be held within the AstraZeneca US Executive Deferral Plan bringing hisnotional interest in ADSs held within the AstraZeneca US Executive Deferral Planas at 27 February 2006 to 75,955 ADSs based on that day's closing price ofUS$46.58. In total, Mr Brennan now has an interest in 6,352 Ordinary Shares and 172,088AstraZeneca ADSs, including the notional interest in ADSs in the AstraZeneca USExecutive Deferral Plan referred to above. G H R MuskerCompany Secretary1 March 2006 This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Astrazeneca